Head-to-head · Cost-Efficiency Index
Henry Meds vs NP2GO
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Henry Meds
People who want a simple, well-known flat-fee program and will pay a premium for the brand.
Visit Henry MedsNP2GO
Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Visit NP2GOThe verdict
Henry Meds takes it, leading the Cost-Efficiency Index 81 to 79. A transparent flat-fee pioneer — the pricing is clean and modelable, but it now sits at the higher end, so the value per dollar has slipped. NP2GO still earns a C — Shoppers inside its 40 served states who want both molecules disclosed and will vet the pharmacy themselves.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Henry Meds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Henry Meds | NP2GO |
|---|---|---|
| Cost-Efficiency Index | 81/100 | 79/100 |
| Semaglutide / mo | $249/mo | $150/mo |
| Tirzepatide / mo | $349/mo | $250/mo |
| Semaglutide / yr (modeled) | $2,988 | $1,800 |
| Tirzepatide / yr (modeled) | $4,188 | $3,000 |
| Coverage | Multi-state | AK, AZ, AR, CA, CO, CT, DE, DC, FL, HI, ID, IL, IA, KS, KY, ME, MD, MA, MI, MN, MT, NE, NV, NH, NJ, NM, NY, ND, OK, OR, PA, RI, SD, TX, UT, VT, VA, WA, WV, WY |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #28 | #33 |
Henry Meds
81/100Where the value is
- Simple, transparent flat-fee model that's easy to model
- Well-established brand
- Both molecules disclosed
The tradeoffs
- Higher per-month cost than many newer entrants weakens value
- Compounded only
NP2GO
79/100Where the value is
- Both molecules disclosed — $150 semaglutide / $250 tirzepatide — for straightforward cost modeling
- Broad 40-state footprint — wider than most non-nationwide operators
- Flat, predictable pricing
The tradeoffs
- 40 states, not all 50 — a coverage gamble that dents its access score
- Not LegitScript-certified — oversight harder to verify
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.